Fecal microbiome and association with outcomes among patients (pts) receiving eribulin (E) plus /- pembrolizumab (P) for hormone receptor positive (HR plus ) metastatic breast cancer (MBC)

被引：3
|
作者：
de Sousa, Romualdo Barroso [1 ]
Ajami, Nadim [2 ]
Keenan, Tanya E. [3 ]
Andrews, Chelsea [3 ]
Pittenger, Jessica L. [3 ]
Wulf, Gerburg [4 ]
Spring, Laura [5 ]
Krop, Ian E. [3 ]
Winer, Eric P. [3 ]
Mittendorf, Elizabeth A. [6 ]
Tolaney, Sara M. [3 ]
机构：
[1] Hosp Sirio Libanes, Brasilia, DF, Brazil
[2] MicrobiomeDx, Houston, TX USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[5] Massachusetts Gen Hosp, Boston, MA 02114 USA
[6] Brigham Womens Hosp, Dana Farber Canc Inst, Boston, MA USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P3-09-16
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-09-16
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Gut and oral microbiota profiling in patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC) receiving pembrolizumab (P) plus eribulin (E): CALADRIO
    Teng, N.
    Dalby, M. J.
    Kiu, R.
    Robinson, T.
    Cortes, M. Gion
    Bermejo De las Heras, B.
    Perez Garcia, J. M.
    Calvo-Martinez, L.
    Prat, A.
    Marquez Vazquez, R.
    Ruiz Borrego, M.
    de la Cruz, S.
    Llombart Cussac, A.
    Curigliano, G.
    Schmid, P.
    Mancino, M.
    Hall, L.
    Robinson, S.
    Cortes, J.
    Malfettone, A.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S129 - S130
  • [2] Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
    Tolaney, Sara M.
    Barroso-Sousa, Romualdo
    Keenan, Tanya
    Trippa, Lorenzo
    Hu, Jiani
    Luis, Ines Maria Vaz Duarte
    Wulf, Gerburg M.
    Spring, Laura
    Sinclair, Natalie Faye
    Andrews, Chelsea
    Pittenger, Jessica Demeo
    Richardson, Edward T.
    Dillon, Deborah
    Lin, Nancy U.
    Overmoyer, Beth
    Partridge, Ann H.
    VanAllen, Eliezer
    Mittendorf, Elizabeth A.
    Winer, Eric P.
    Krop, Ian E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Real world clinical outcomes of palbociclib in hormone receptor positive (HR plus ) metastatic breast cancer (MBC) patients.
    Eziokwu, Akaolisa Samuel
    Varella, Leticia
    Kruse, Megan Lynn
    Jia, Xuefei
    Moore, Halle C. F.
    Budd, George Thomas
    Abraham, Jame
    Montero, Alberto J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Gut microbiome signatures correlate with overall survival among patients receiving eribulin with or without pembrolizumab for hormone receptor-positive metastatic breast cancer
    Barroso-Sousa, Romualdo
    Li, Tianyu
    Damania, Ashish V.
    DiLullo, Molly K.
    Keenan, Tanya
    Wulf, Gerburg M.
    Spring, Laura M.
    Mittendorf, Elizabeth A.
    Ligibel, Jennifer A.
    Ajami, Nadim J.
    Wargo, Jennifer
    Tayob, Nabihah
    Tolaney, Sara
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [5] Clinical characteristics, demographics, and outcomes in hormone-receptor (HR plus ) positive metastatic breast cancer (MBC) patients treated with palbociclib.
    Landry, Chrystal Ann
    Dimitrova, Maya
    Ru, Meng
    Teplinsky, Eleonora
    Tiersten, Amy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
    Barroso-Sousa, Romualdo
    Krop, Ian E.
    Trippa, Lorenzo
    Tan-Wasielewski, Zhenying
    Li, Tianyu
    Osmani, Wafa
    Andrews, Chelsea
    Dillon, Deborah
    Richardson, Edward T.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Schoenfeld, Jonathan Daniel
    Tolaney, Sara M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Genomic testing and uptake of alteration-targeted therapies among patients with hormone-receptor positive (HR plus ) metastatic breast cancer (MBC)
    Mahadevia, Himil
    Chandra, Simran
    Gosch, Kensey
    Khamees, Ibrahim
    Sharma, Parth
    Gast, Kelly C.
    Pluard, Timothy J.
    Hensing, Whitney L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Src Kinase Inhibition with AZD0530 Plus Anastrozole in Postmenopausal Hormone Receptor Positive (HR plus ) Metastatic Breast Cancer (MBC)
    Pegram, M.
    Silva, O.
    Higgins, C.
    Tukia, K.
    Avisar, E.
    Stuart, M.
    Slingerland, J.
    [J]. CANCER RESEARCH, 2010, 70
  • [9] registHER: Treatment outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Tripathy, D.
    Kaufman, P.
    Brufsky, A.
    Mayer, M.
    Yood, M.
    Wang, L.
    Brammer, M.
    Yardley, D.
    Tan-Chiu, E.
    Rugo, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Metastatic patterns and outcomes by HER2 and hormone receptor (HR) status in patients (pts) with metastatic breast cancer (mBC)
    Yuan, Qianyu
    Castellanos, Emily
    Fidyk, Erin
    Schwed, Karen
    Estevez, Melissa
    Nemeth, Sheila
    Linzmayer, Robin
    Cohen, Aaron B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345